Fernanda Fries da Silva, Josiane Delgado Paz, Raoní Scheibler Rambo, Guilherme Arraché Gonçalves, Mauro Neves Muniz, Alexia de Matos Czeczot, Marcia Alberton Perelló, Andresa Berger, Laura Calle González, Lovaine Silva Duarte, Anelise Baptista da Silva, Carlos Alexandre Sanchez Ferreira, Sílvia Dias de Oliveira, Sidnei Moura, Cristiano Valim Bizarro, Luiz Augusto Basso, Pablo Machado
{"title":"Unveiling the Antimycobacterial Potential of Novel 4-Alkoxyquinolines: Insights into Selectivity, Mechanism of Action, and In Vivo Exposure","authors":"Fernanda Fries da Silva, Josiane Delgado Paz, Raoní Scheibler Rambo, Guilherme Arraché Gonçalves, Mauro Neves Muniz, Alexia de Matos Czeczot, Marcia Alberton Perelló, Andresa Berger, Laura Calle González, Lovaine Silva Duarte, Anelise Baptista da Silva, Carlos Alexandre Sanchez Ferreira, Sílvia Dias de Oliveira, Sidnei Moura, Cristiano Valim Bizarro, Luiz Augusto Basso, Pablo Machado","doi":"10.1021/acs.jmedchem.4c01302","DOIUrl":null,"url":null,"abstract":"This work presents a comprehensive investigation into the design, synthesis, and evaluation of a novel series of 4-alkoxyquinolines as potential antimycobacterial agents. The design approach, which combined molecular simplification and chain extension, resulted in compounds with potent and selective activity against both drug-susceptible and multidrug-resistant <i>Mycobacterium tuberculosis</i> strains. The lead molecule, targeting the cytochrome <i>bc</i><sub>1</sub> complex, exhibited favorable kinetic solubility and remarkable chemical stability under acidic conditions. Despite <i>in vitro</i> ADME evaluations showing low permeability and high metabolism in rat microsomes, the lead compound exhibited bacteriostatic activity in a murine macrophage model of TB infection and demonstrated promising <i>in vivo</i> exposure following gavage in mice, with an AUC<sub>0–<i>t</i></sub> of 127.5 ± 5.7 μM h. To the best of our knowledge, for the first time, a simplified structure from 2-(quinolin-4-yloxy)acetamides has shown such potential. These findings suggest a new avenue for exploring this chemical class as a source of antituberculosis drug candidates.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"262 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.4c01302","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
This work presents a comprehensive investigation into the design, synthesis, and evaluation of a novel series of 4-alkoxyquinolines as potential antimycobacterial agents. The design approach, which combined molecular simplification and chain extension, resulted in compounds with potent and selective activity against both drug-susceptible and multidrug-resistant Mycobacterium tuberculosis strains. The lead molecule, targeting the cytochrome bc1 complex, exhibited favorable kinetic solubility and remarkable chemical stability under acidic conditions. Despite in vitro ADME evaluations showing low permeability and high metabolism in rat microsomes, the lead compound exhibited bacteriostatic activity in a murine macrophage model of TB infection and demonstrated promising in vivo exposure following gavage in mice, with an AUC0–t of 127.5 ± 5.7 μM h. To the best of our knowledge, for the first time, a simplified structure from 2-(quinolin-4-yloxy)acetamides has shown such potential. These findings suggest a new avenue for exploring this chemical class as a source of antituberculosis drug candidates.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.